1. Home
  2. MRKR vs AIMD Comparison

MRKR vs AIMD Comparison

Compare MRKR & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$1.19

Market Cap

16.6M

Sector

Health Care

ML Signal

HOLD

AIMD

Ainos Inc.

HOLD

Current Price

$2.06

Market Cap

16.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRKR
AIMD
Founded
N/A
1984
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.6M
16.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MRKR
AIMD
Price
$1.19
$2.06
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$10.25
N/A
AVG Volume (30 Days)
271.0K
38.7K
Earning Date
11-13-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,694,988.00
$113,037.00
Revenue This Year
N/A
N/A
Revenue Next Year
$9.06
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
178.19
52 Week Low
$0.81
$1.78
52 Week High
$5.95
$5.00

Technical Indicators

Market Signals
Indicator
MRKR
AIMD
Relative Strength Index (RSI) 63.24 32.46
Support Level $1.15 $2.02
Resistance Level $1.27 $2.27
Average True Range (ATR) 0.10 0.18
MACD 0.03 0.01
Stochastic Oscillator 87.50 20.15

Price Performance

Historical Comparison
MRKR
AIMD

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

About AIMD Ainos Inc.

Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.

Share on Social Networks: